scispace - formally typeset
Search or ask a question

Showing papers by "Michel A. Duchosal published in 2004"


Journal ArticleDOI
TL;DR: A new mechanism in plaque vulnerability is suggested demonstrating that angiotensin II, within the context of hypertension and hypercholesterolemia, independently from its hemodynamic effect behaves as a local modulator promoting the induction of vulnerable plaques probably via a T helper switch.
Abstract: Rupture of vulnerable plaques is the main cause of acute cardiovascular events. However, mechanisms responsible for transforming a stable into a vulnerable plaque remain elusive. Angiotensin II, a key regulator of blood pressure homeostasis, has a potential role in atherosclerosis. To study the contribution of angiotensin II in plaque vulnerability, we generated hypertensive hypercholesterolemic ApoE −/− mice with either normal or endogenously increased angiotensin II production (renovascular hypertension models). Hypertensive high angiotensin II ApoE −/− mice developed unstable plaques, whereas in hypertensive normal angiotensin II ApoE −/− mice plaques showed a stable phenotype. Vulnerable plaques from high angiotensin II ApoE −/− mice had thinner fibrous cap ( P P P −/− mice. Moreover, in mice with high angiotensin II, a skewed T helper type 1-like phenotype was observed. Splenocytes from high angiotensin II ApoE −/− mice produced significantly higher amounts of interferon (IFN)-γ than those from ApoE −/− mice with normal angiotensin II; secretion of IL4 and IL10 was not different. In addition, we provide evidence for a direct stimulating effect of angiotensin II on lymphocyte IFN-γ production. These findings suggest a new mechanism in plaque vulnerability demonstrating that angiotensin II, within the context of hypertension and hypercholesterolemia, independently from its hemodynamic effect behaves as a local modulator promoting the induction of vulnerable plaques probably via a T helper switch.

142 citations


Journal ArticleDOI
TL;DR: A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection, and is currently being applied in a clinical study assessing the imatinIB plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients.

68 citations


Journal ArticleDOI
09 Dec 2004-Vaccine
TL;DR: It is indicated that the rE1 glycoprotein could constitute a non-replicating rubella vaccine.

9 citations